Mark W. Lowdell

7.9k total citations
148 papers, 4.9k citations indexed

About

Mark W. Lowdell is a scholar working on Immunology, Surgery and Oncology. According to data from OpenAlex, Mark W. Lowdell has authored 148 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 68 papers in Immunology, 36 papers in Surgery and 33 papers in Oncology. Recurrent topics in Mark W. Lowdell's work include Immune Cell Function and Interaction (55 papers), T-cell and B-cell Immunology (33 papers) and Tissue Engineering and Regenerative Medicine (27 papers). Mark W. Lowdell is often cited by papers focused on Immune Cell Function and Interaction (55 papers), T-cell and B-cell Immunology (33 papers) and Tissue Engineering and Regenerative Medicine (27 papers). Mark W. Lowdell collaborates with scholars based in United Kingdom, United States and Sweden. Mark W. Lowdell's co-authors include Martin Birchall, Stephen Mackinnon, Janet North, Edward Samuel, H. G. Prentice, Paolo De Coppi, Andrea Knight, May Sabry, Sam M. Janes and Kirsty Thomson and has published in prestigious journals such as Proceedings of the National Academy of Sciences, The Lancet and Journal of Clinical Oncology.

In The Last Decade

Mark W. Lowdell

141 papers receiving 4.8k citations

Peers

Countries citing papers authored by Mark W. Lowdell

Since Specialization

Citations

This map shows the geographic impact of Mark W. Lowdell's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark W. Lowdell with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark W. Lowdell more than expected).

Fields of papers citing papers by Mark W. Lowdell

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Mark W. Lowdell. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark W. Lowdell. The network helps show where Mark W. Lowdell may publish in the future.

Co-authorship network of co-authors of Mark W. Lowdell

This figure shows the co-authorship network connecting the top 25 collaborators of Mark W. Lowdell. A scholar is included among the top collaborators of Mark W. Lowdell based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Mark W. Lowdell. Mark W. Lowdell is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Expanded adaptive NKG2C+ NK cells exhibit potent ADCC and functional responses against HBV-infected hepatoma cell lines 2025 ·Cytotherapy ·(unknown), (unknown), Benjamin Hammond, (unknown), (unknown), (unknown), (unknown), (unknown), Thomas Fernandez, Sabine Kinloch, Fiona Burns, Patrick Kennedy, Douglas MacDonald, Mala K. Maini, Upkar S. Gill, Xiaodong Zhuang, Mark W. Lowdell, Karl‐Johan Malmberg, Ebba Sohlberg, Dimitra Peppa	0
2	Defining minimal criteria for peer-reviewed reporting of mesenchymal stromal cell clinical trials for autoimmune diseases 2025 ·Cytotherapy ·Lindsay C. Davies, Lucie Biard, Damián García‐Olmo, Gary S. Gilkeson, Massimiliano Gnecchi, Joanne Kurtzberg, Gesine Kögler, Katarina Le Blanc, Mark W. Lowdell, Yves‐Marie Pers, Lingyun Sun, Karin Tarte, Antonio Uccelli, Fermín Sánchez‐Guijo, Dominique Farge	1
3	Considerations for manufacturing of cell and gene medicines for clinical development 2024 ·Cytotherapy ·Mark W. Lowdell	2
4	ATMPs from academia to industry getting it right first time (GIRFT) 2022 ·The biomedical & life sciences collection. ·Mark W. Lowdell	0
5	Killers at the crossroads: The use of innate immune cells in adoptive cellular therapy of cancer 2020 ·Stem Cells Translational Medicine ·May Sabry, Mark W. Lowdell	21
6	Using a Three-Dimensional Collagen Matrix to Deliver Respiratory Progenitor Cells to Decellularized Trachea In Vivo 2019 ·Tissue Engineering Part C Methods ·Nicholas Hamilton, Robert E. Hynds, Kate H.C. Gowers, Angela Tait, Colin R. Butler, Colin Hopper, Alan J. Burns, Martin Birchall, Mark W. Lowdell, Sam M. Janes	21
7	T-cell receptor gene-modified cells: past promises, present methodologies and future challenges 2019 ·Cytotherapy ·(unknown), Emma Morris, Mark W. Lowdell	15
8	Umbilical cord–derived mesenchymal stromal cells in cardiovascular disease: review of preclinical and clinical data 2019 ·Cytotherapy ·Martina Colicchia, Daniel A. Jones, (unknown), (unknown), (unknown), Krishnaraj S. Rathod, Jessry Veerapen, Mark W. Lowdell, Anthony Mathur	23
9	Cost of Stem Cell-Based Tissue-Engineered Airway Transplants in the United Kingdom: Case Series 2015 ·Tissue Engineering Part A ·Emily J Culme-Seymour, (unknown), Laura Vallejo‐Torres, Carla Carvalho, Leanne Partington, Claire Crowley, Nicholas Hamilton, (unknown), Colin R. Butler, Martin J. Elliott, Martin Birchall, Mark W. Lowdell, Chris Mason	18
10	Two-Stage Priming of Allogeneic Natural Killer Cells for the Treatment of Patients with Acute Myeloid Leukemia: A Phase I Trial 2015 ·PLoS ONE ·Panagiotis Kottaridis, Janet North, (unknown), Chloë Marden, Edward Samuel, (unknown), Sarah Grace, Mark W. Lowdell	49
11	Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads 2015 ·Bone Marrow Transplantation ·Stephanie Verfuerth, Pedro Santos e Sousa, (unknown), (unknown), Marco Peters, Stephen Mackinnon, Mark W. Lowdell, Ronjon Chakraverty, Edward Samuel	10
12	CMV-Independent Lysis of Glioblastoma by Ex Vivo Expanded/Activated Vdelta1+ gamma-delta T Cells 2013 ·PLoS ONE ·Andrea Knight, Hilal Arnouk, William J. Britt, G. Yancey Gillespie, (unknown), Lualhati Harkins, (unknown), Mark W. Lowdell, Lawrence S. Lamb	1
13	Tracking stem cells in tissue-engineered organs using magnetic nanoparticles 2013 ·Nanoscale ·(unknown), Mark W. Lowdell, Martin Birchall, Nguyễn Thị Kim Thanh	57
14	Tumor‐primed natural killer cells from patients with multiple myeloma lyse autologous, NK‐resistant, bone marrow‐derived malignant plasma cells 2011 ·American Journal of Hematology ·Eirini Katodritou, Evangelos Terpos, Janet North, Panagiotis Kottaridis, Evgenia Verrou, (unknown), (unknown), (unknown), (unknown), (unknown), Dimitrios Kapetanos, Konstantinos Zervas, Mark W. Lowdell	15
15	The role of Vδ2-negative γδ T cells during cytomegalovirus reactivation in recipients of allogeneic stem cell transplantation 2010 ·Blood ·Andrea Knight, J. Alejandro Madrigal, Sarah Grace, (unknown), Panagiotis Kottaridis, Stephen Mackinnon, Paul Travers, Mark W. Lowdell	159
16	Tumor-Primed Human Natural Killer Cells Lyse NK-Resistant Tumor Targets: Evidence of a Two-Stage Process in Resting NK Cell Activation 2007 ·The Journal of Immunology ·Janet North, (unknown), Chloë Marden, (unknown), (unknown), Cristina Navarrete, Robert J. Anderson, Mark W. Lowdell	81
17	Functional impairment of human T-lymphocytes following PHA-induced expansion and retroviral transduction: implications for gene therapy 2002 ·Gene Therapy ·Rafael F. Duarte, Frederick Chen, Mark W. Lowdell, Mike Potter, María L. Lamana, H. G. Prentice, J. Alejandro Madrigal	42
18	The influence of exogenous peptide on β 2 -microglobulin exchange in the HLA complex: analysis in real-time 1998 ·Immunogenetics ·Claire Morgan, (unknown), Alejandra Solache, Mark W. Lowdell, (unknown), S B Cohen, Peter Parham, J. Alejandro Madrigal, David Newman	10
19	Immunocytochemical Detection of Breast Cancer Cells: A Comparison of Three Attachment Factors 1997 ·Journal of Hematotherapy ·Panteli Theocharous, Mark W. Lowdell, (unknown), H. G. Prentice	9
20	Decline in CTL and Antibody Responses to HIV-1 p17 and p24 Antigens in HIV-1-Infected Hemophiliacs Irrespective of Disease Progression. A 5-Year Follow-up Study 1992 ·AIDS Research and Human Retroviruses ·Carol O’Toole, Susan M. Graham, Mark W. Lowdell, Daniel Chargelegue, H. S. Marsden, B T Colvin	7

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact